Paratek Pharmaceuticals (PRTK) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Paratek Pharmaceuticals (NASDAQ:PRTK) posted its quarterly earnings data on Thursday. The specialty pharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.03), Yahoo Finance reports. Paratek Pharmaceuticals had a negative return on equity of 100.84% and a negative net margin of 1,236.38%. The company had revenue of $5.07 million for the quarter, compared to the consensus estimate of $5.00 million.

Paratek Pharmaceuticals (NASDAQ PRTK) traded down $0.30 during trading hours on Friday, reaching $12.80. 473,100 shares of the company’s stock were exchanged, compared to its average volume of 511,389. Paratek Pharmaceuticals has a 52-week low of $11.85 and a 52-week high of $29.00. The firm has a market capitalization of $407.37, a price-to-earnings ratio of -3.43 and a beta of 0.35. The company has a debt-to-equity ratio of 0.49, a quick ratio of 10.53 and a current ratio of 10.53.

In other news, VP Adam Woodrow sold 14,333 shares of the company’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $13.87, for a total transaction of $198,798.71. Following the transaction, the vice president now directly owns 62,367 shares in the company, valued at $865,030.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert S. Radie sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $14.22, for a total transaction of $42,660.00. Following the transaction, the director now owns 9,330 shares in the company, valued at $132,672.60. The disclosure for this sale can be found here. Insiders have sold 40,664 shares of company stock worth $573,226 over the last quarter. 4.90% of the stock is owned by company insiders.

PRTK has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 target price on the stock in a research report on Wednesday, January 10th. Cantor Fitzgerald set a $50.00 target price on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday. HC Wainwright lifted their target price on shares of Paratek Pharmaceuticals from $43.00 to $55.00 and gave the company a “buy” rating in a research report on Friday. UBS Group lowered shares of Paratek Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a research report on Friday. Finally, Raymond James Financial reiterated an “outperform” rating and set a $36.00 target price on shares of Paratek Pharmaceuticals in a research report on Friday. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $40.75.

COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://ledgergazette.com/2018/03/02/paratek-pharmaceuticals-prtk-posts-quarterly-earnings-results-misses-estimates-by-0-03-eps.html.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Earnings History for Paratek Pharmaceuticals (NASDAQ:PRTK)

Leave a Reply